Edition:
United States

Northwest Biotherapeutics Inc (NWBO.OQ)

NWBO.OQ on NASDAQ Stock Exchange Capital Market

0.45USD
4:00pm EDT
Change (% chg)

$-0.01 (-1.87%)
Prev Close
$0.46
Open
$0.47
Day's High
$0.47
Day's Low
$0.43
Volume
61,258
Avg. Vol
149,636
52-wk High
$12.10
52-wk Low
$0.43

NWBO.OQ

Chart for NWBO.OQ

About

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid... (more)

Overall

Beta: 2.13
Market Cap(Mil.): $52.12
Shares Outstanding(Mil.): 113.57
Dividend: --
Yield (%): --

Financials

  NWBO.OQ Industry Sector
P/E (TTM): -- 42.42 37.52
EPS (TTM): -0.97 -- --
ROI: -- -9.34 14.48
ROE: -- -9.70 15.65

BRIEF-Northwest Biotherapeutics says will sell to investors about 7.4 mln shares at 50 cents per share

* Entered into agreements with two new institutional investors for direct offering with gross proceeds of $3.7 million

Jul 05 2016

BRIEF-Northwest Biotherapeutics files for non-timely 10-Q

* Requires additional time for company and independent registered public accounting firm to complete review process Source text: http://1.usa.gov/1rSsMoe Further company coverage:

May 10 2016

BRIEF-Northwest Biotherapeutics extends exercise period of series B warrants

* On may 2, co and holders of co's series B warrants agreed to extend exercise period of series b warrants from may 2, 2016 to may 23, 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 03 2016

BRIEF-Northwest Biotherapeuticsannounces operations updates

* Reached agreement with three parties, in regard to three combination treatments, for three cancers in three phase ii trials

May 02 2016

UPDATE 1-Woodford trust changes strategy, drops capital raising

LONDON, March 22 An investment trust launched less than a year ago by star fund manager Neil Woodford is increasing its focus on early-stage companies and abandoning near-term plans to raise more capital, it said on Tuesday, after its net asset value fell nearly 3 percent.

Mar 22 2016

BRIEF-Northwest biotherapeutics files for non-timely 10-k - sec filing

* Says requires additional time to complete its year end procedures

Mar 15 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.